The BCR-ABL qualitative test performed on EDTA whole blood is a specialized molecular assay designed to detect the presence of the BCR-ABL fusion gene transcript, commonly known as the Philadelphia chromosome. This genetic abnormality is a hallmark of chronic myeloid leukemia (CML) and certain types of acute lymphoblastic leukemia (ALL). By utilizing reverse transcription-polymerase chain reaction (RT-PCR) technology, the test identifies whether the specific gene rearrangement is present or absent in the patient's blood sample. It serves as a crucial initial diagnostic tool to confirm clinical suspicion, guide targeted therapies, and support personalized treatment planning for hematological malignancies.